{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:05Z","timestamp":1790963585865,"version":"4.1.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Because of its role in mediating both B cell and Fc receptor signaling, Bruton\u2019s tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor\u2013mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils. We evaluated evobrutinib in preclinical models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity. In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by reduction of disease severity and histological damage. In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody production and plasma cell numbers, and normalized B and T cell subsets. In the RA model, efficacy was achieved despite failure to reduce autoantibodies. Pharmacokinetic\/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models. In addition, evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model. Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells. Taken together, our data show that evobrutinib is a promising molecule for the chronic treatment of B cell\u2013driven autoimmune disorders.<\/jats:p>","DOI":"10.4049\/jimmunol.1800583","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T22:35:19Z","timestamp":1555367719000},"page":"2888-2906","source":"Crossref","is-referenced-by-count":138,"title":["Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models"],"prefix":"10.1093","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-9656","authenticated-orcid":false,"given":"Philipp","family":"Haselmayer","sequence":"first","affiliation":[{"name":"Translational Innovation Platform Immunology, Merck KGaA , Darmstadt 64293 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Camps","sequence":"additional","affiliation":[{"name":"Immunology, Merck Serono , 1201 Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Liu-Bujalski","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morandi","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Head","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"O\u2019Mahony","sequence":"additional","affiliation":[{"name":"Eurofins DiscoverX Corporation , South San Francisco, CA 94080"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C","family":"Zimmerli","sequence":"additional","affiliation":[{"name":"Translational Innovation Platform Immunology, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bruns","sequence":"additional","affiliation":[{"name":"Translational Innovation Platform Immunology, Merck KGaA , Darmstadt 64293 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T","family":"Bender","sequence":"additional","affiliation":[{"name":"Translational Innovation Platform Immunology, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Translational Pharmacology, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-6782","authenticated-orcid":false,"given":"Roland","family":"Grenningloh","sequence":"additional","affiliation":[{"name":"Translational Innovation Platform Immunology, EMD Serono Research and Development Institute , Billerica, MA 01821"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"2025030417562204400_r1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cellsig.2010.03.001","article-title":"The Src, Syk, and Tec family kinases: distinct types of molecular switches","volume":"22","author":"Bradshaw","year":"2010","journal-title":"Cell. Signal."},{"key":"2025030417562204400_r2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000078339","article-title":"The role of Tec family kinases in myeloid cells","volume":"134","author":"Schmidt","year":"2004","journal-title":"Int. Arch. Allergy Immunol."},{"key":"2025030417562204400_r3","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene"},{"key":"2025030417562204400_r4","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1073\/pnas.94.21.11526","article-title":"Phosphorylation of two regulatory tyrosine residues in the activation of Bruton\u2019s tyrosine kinase via alternative receptors","volume":"94","author":"Wahl","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417562204400_r5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1189\/jlb.0513307","article-title":"Bruton\u2019s tyrosine kinase--an integral protein of B cell development that also has an essential role in the innate immune system","volume":"95","author":"L\u00f3pez-Herrera","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"2025030417562204400_r6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr. Biol."},{"key":"2025030417562204400_r7","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"key":"2025030417562204400_r8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"2025030417562204400_r9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"2025030417562204400_r10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. [Published erratum appears in 1993 Nature 364: 362.]","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"2025030417562204400_r11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J. Immunol."},{"key":"2025030417562204400_r12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1196\/annals.1358.014","article-title":"Human B cell tolerance and its failure in rheumatoid arthritis","volume":"1062","author":"Samuels","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030417562204400_r13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.molimm.2008.08.278","article-title":"Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells","volume":"46","author":"Halcomb","year":"2008","journal-title":"Mol. Immunol."},{"key":"2025030417562204400_r14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/1074-7613(95)90114-0","article-title":"Defective B cell development and function in Btk-deficient mice","volume":"3","author":"Khan","year":"1995","journal-title":"Immunity"},{"key":"2025030417562204400_r15","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","article-title":"The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Lee","year":"2011","journal-title":"Rheumatol. Int."},{"key":"2025030417562204400_r16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kel065","article-title":"Synovial fibroblasts: key players in rheumatoid arthritis","volume":"45","author":"Huber","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2025030417562204400_r17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"2025030417562204400_r18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/ar3465","article-title":"Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models","volume":"13","author":"Pathak","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"2025030417562204400_r19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cmi.2012.64","article-title":"B-cell-targeted therapies in systemic lupus erythematosus","volume":"10","author":"Chan","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"2025030417562204400_r20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40259-013-0015-8","article-title":"B-cell targeted therapies in systemic lupus erythematosus: successes and challenges","volume":"27","author":"Harvey","year":"2013","journal-title":"BioDrugs"},{"key":"2025030417562204400_r21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/14712598.2014.895810","article-title":"Update on B-cell targeted therapies for systemic lupus erythematosus","volume":"14","author":"Mok","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"2025030417562204400_r22","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2025030417562204400_r23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"2025030417562204400_r24","first-page":"814869","article-title":"Targeting spleen tyrosine kinase-Bruton\u2019s tyrosine kinase axis for immunologically mediated glomerulonephritis","volume":"2014","author":"Chen","year":"2014","journal-title":"Biomed Res. Int."},{"key":"2025030417562204400_r25","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417562204400_r26","doi-asserted-by":"crossref","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"2025030417562204400_r27","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.38047","article-title":"Suppression of glomerulonephritis in lupus-prone NZB \u00d7 NZW mice by RN486, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"65","author":"Mina-Osorio","year":"2013","journal-title":"Arthritis Rheum."},{"key":"2025030417562204400_r28","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","article-title":"Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis","volume":"191","author":"Rankin","year":"2013","journal-title":"J. Immunol."},{"key":"2025030417562204400_r29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.drudis.2014.03.028","article-title":"Bruton\u2019s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"19","author":"Whang","year":"2014","journal-title":"Drug Discov. Today"},{"key":"2025030417562204400_r30","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"2025030417562204400_r31","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417562204400_r32","first-page":"277","article-title":"International nonproprietary names for pharmaceutical substances (INN)","volume":"30","author":"World Health Organization","year":"2016","journal-title":"WHO Drug Inf."},{"key":"2025030417562204400_r33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fimmu.2014.00233","article-title":"Characterization of novel PI3K\u03b4 inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies","volume":"5","author":"Haselmayer","year":"2014","journal-title":"Front. Immunol."},{"key":"2025030417562204400_r34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/1087057113505324","article-title":"Building predictive models for mechanism-of-action classification from phenotypic assay data sets","volume":"18","author":"Berg","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"2025030417562204400_r35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2016.01.012","article-title":"Btk inhibition treats TLR7\/IFN driven murine lupus","volume":"164","author":"Bender","year":"2016","journal-title":"Clin. Immunol."},{"key":"2025030417562204400_r36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.111.181545","article-title":"Antiarthritis effect of a novel Bruton\u2019s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic\/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy","volume":"338","author":"Liu","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025030417562204400_r37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem. Biol."},{"key":"2025030417562204400_r38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni.3326","article-title":"Self-reactive IgE exacerbates interferon responses associated with autoimmunity","volume":"17","author":"Henault","year":"2016","journal-title":"Nat. Immunol."},{"key":"2025030417562204400_r39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.coi.2013.10.003","article-title":"The deleterious role of basophils in systemic lupus erythematosus","volume":"25","author":"Pellefigues","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"2025030417562204400_r40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11882-011-0216-5","article-title":"Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus","volume":"11","author":"Charles","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"2025030417562204400_r41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2025030417562204400_r42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vascn.2009.10.001","article-title":"Chemical target and pathway toxicity mechanisms defined in primary human cell systems","volume":"61","author":"Berg","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2025030417562204400_r43","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"2025030417562204400_r44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23775","article-title":"Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia","volume":"90","author":"Mannis","year":"2015","journal-title":"Am. J. Hematol."},{"key":"2025030417562204400_r45","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.21929","article-title":"Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus","volume":"54","author":"Tisseverasinghe","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2025030417562204400_r46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/B978-0-12-374994-9.10048-8","volume-title":"Systemic Lupus Erythematosus","author":"Monrad","year":"2011","edition":"5th Ed."},{"key":"2025030417562204400_r47","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0022-3565(24)38953-0","article-title":"A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog","volume":"295","author":"Abel\u00f6","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025030417562204400_r48","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2025030417562204400_r49","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia. [Published erratum appears in 2014 N. Engl. J. Med. 370: 2547.]","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2025030417562204400_r50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.111.187740","article-title":"RN486, a selective Bruton\u2019s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025030417562204400_r51","first-page":"37","article-title":"Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia","volume":"8","author":"Chavez","year":"2013","journal-title":"Core Evid."},{"key":"2025030417562204400_r52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr. Oncol."},{"key":"2025030417562204400_r53","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.39657","article-title":"Bruton\u2019s tyrosine kinase deficiency inhibits autoimmune arthritis in mice but fails to block immune complex-mediated inflammatory arthritis","volume":"68","author":"Nyhoff","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"2025030417562204400_r54","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4049\/jimmunol.1300125","article-title":"Bruton\u2019s tyrosine kinase promotes persistence of mature anti-insulin B cells","volume":"192","author":"Bonami","year":"2014","journal-title":"J. Immunol."},{"key":"2025030417562204400_r55","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton\u2019s tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2025030417562204400_r56","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.4049\/jimmunol.171.4.1850","article-title":"Reduced dosage of Bruton\u2019s tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-\/- mice","volume":"171","author":"Whyburn","year":"2003","journal-title":"J. Immunol."},{"key":"2025030417562204400_r57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-016-0988-z","article-title":"HM71224, a novel Bruton\u2019s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"2025030417562204400_r58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"2025030417562204400_r59","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1002\/1521-4141(2002010)32:10<2915::AID-IMMU2915>3.0.CO;2-4","article-title":"Expression of FcgammaRIII is required for development of collagen-induced arthritis","volume":"32","author":"D\u00edaz de St\u00e5hl","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"2025030417562204400_r60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0065-2776(04)82005-4","article-title":"The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease","volume":"82","author":"Monach","year":"2004","journal-title":"Adv. Immunol."},{"key":"2025030417562204400_r61","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1074\/jbc.M708935200","article-title":"The tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation","volume":"283","author":"Lee","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2025030417562204400_r62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bone.2013.11.025","article-title":"The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss","volume":"60","author":"Shinohara","year":"2014","journal-title":"Bone"},{"key":"2025030417562204400_r63","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"2025030417562204400_r64","doi-asserted-by":"crossref","first-page":"e0181782","DOI":"10.1371\/journal.pone.0181782","article-title":"Bruton\u2019s tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care","volume":"12","author":"Gillooly","year":"2017","journal-title":"PLoS One"},{"key":"2025030417562204400_r65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2016.00213","article-title":"K\/BxN serum-transfer arthritis as a model for human inflammatory arthritis","volume":"7","author":"Christensen","year":"2016","journal-title":"Front. Immunol."},{"key":"2025030417562204400_r66","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.4049\/jimmunol.170.8.4318","article-title":"Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis","volume":"170","author":"Kagari","year":"2003","journal-title":"J. Immunol."},{"key":"2025030417562204400_r67","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.4049\/jimmunol.1002813","article-title":"The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner","volume":"186","author":"Gottar-Guillier","year":"2011","journal-title":"J. Immunol."},{"key":"2025030417562204400_r68","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J. Med. Chem."},{"key":"2025030417562204400_r69","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.1701489","article-title":"Bruton\u2019s tyrosine kinase is not essential for B cell survival beyond early developmental stages","volume":"200","author":"Nyhoff","year":"2018","journal-title":"J. Immunol."},{"key":"2025030417562204400_r70","article-title":"ABBV-105, a selective and irreversible inhibitor of Bruton\u2019s tyrosine kinase, is efficacious in multiple preclinical models of inflammation","author":"Goess","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"2025030417562204400_r71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-017-1402-1","article-title":"HM71224, a selective Bruton\u2019s tyrosine kinase inhibitor, attenuates the development of murine lupus","volume":"19","author":"Kim","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"2025030417562204400_r72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-017-1500-0","article-title":"Highly selective inhibition of Bruton\u2019s tyrosine kinase attenuates skin and brain disease in murine lupus","volume":"20","author":"Chalmers","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"2025030417562204400_r73","doi-asserted-by":"crossref","first-page":"e90111","DOI":"10.1172\/jci.insight.90111","article-title":"Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN\u03b1-driven lupus nephritis","volume":"2","author":"Katewa","year":"2017","journal-title":"JCI Insight"},{"key":"2025030417562204400_r74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1172\/JCI110651","article-title":"Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA","volume":"70","author":"Steinberg","year":"1982","journal-title":"J. Clin. Invest."},{"key":"2025030417562204400_r75","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.4049\/jimmunol.0900367","article-title":"Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene","volume":"183","author":"Kendall","year":"2009","journal-title":"J. Immunol."},{"key":"2025030417562204400_r76","doi-asserted-by":"crossref","first-page":"46029","DOI":"10.1038\/srep46029","article-title":"Mediation of transitional B cell maturation in the absence of functional Bruton\u2019s tyrosine kinase","volume":"7","author":"Tanwar","year":"2017","journal-title":"Sci. Rep."},{"key":"2025030417562204400_r77","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"2025030417562204400_r78","article-title":"Inhibition of Bruton\u2019s tyrosine kinase (BTK) prevents inflammatory macrophage differentiation: a potential role in RA and SLE","volume-title":"Arthritis Rheumatol.","author":"Alankus","year":"2018"},{"key":"2025030417562204400_r79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/10\/2888\/61872472\/ji1800583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/10\/2888\/61872472\/ji1800583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:14:25Z","timestamp":1741119265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/202\/10\/2888\/7952400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1800583","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5]]}}}